Recently, The Lancet magazine published a research paper on the front page of official website: Efficacy, Safety and Immunogenicity of Oral Recombinant Helicobacter pylori Vaccine in Children in China: A Randomized, Double-blind, Placebo-controlled, Phase III Trial (efficiency, Security and immunity of oral helicobacter pylori and urokin-induced helicobacter pylori vaccine in children: a random, double-blind, placebo-controlled, phase III clinical trial), reported the important results of phase III clinical research on oral recombinant Helicobacter pylori vaccine independently developed in China. A randomized, double-blind placebo-controlled trial of 4464 children aged 6- 15 years showed that oral recombinant Helicobacter pylori vaccine has good safety and immunogenicity, and can effectively prevent Helicobacter pylori infection, thus reducing the incidence of gastritis, gastroduodenal ulcer and gastric cancer caused by this bacterial infection. In the same period, The Lancet also published Professor Philip Sutton's special comment on this research: "... vacuum-induced protection against Helicobacter pylori infection is an important step forward on the road to vacuum. Prevent gastric cancer. This is expected to rekindle interest in this important field and encourage increased investment to promote new projects into advanced clinical trials. " Vaccine-induced protection against Helicobacter pylori infection is an important step on the road of vaccine protection for gastric cancer. It is hoped that this will rekindle interest in this important field and encourage increased investment to promote new projects through advanced clinical trials)

Gastritis, gastric ulcer and gastric cancer are serious diseases that endanger human health. Helicobacter pylori (Hp) is the most important pathogen of gastric diseases, and WHO has identified it as the primary carcinogen of gastric cancer. 1982, Marshall and Warren discovered Helicobacter pylori, and revealed the pathogenic mechanism of chronic gastritis and gastric and duodenal ulcer caused by this bacterium, and won the Nobel Prize in 2005. In China, the infection rate of Helicobacter pylori exceeds 53%, and the patients with chronic gastritis and gastric and duodenal ulcers exceed 200 million. In 20 12 years, the incidence of gastric cancer has ranked second, the number of gastric cancer deaths has exceeded 200,000, and the cost of treating diseases caused by Hp has exceeded10 billion yuan. Antibiotics have been used to treat Hp-related diseases in clinic, but the abuse of antibiotics has led to the continuous production of Hp-resistant bacteria, and the number of patients has not decreased due to treatment. It is urgent to find new prevention and treatment methods. Vaccination is the most effective strategy to prevent infectious diseases, which can not only control its spread and infection from the source, but also greatly reduce the cost of prevention and treatment. With the support of 22 projects, including the National 863 Program, the Key Science and Technology Program and the Major New Drug Creation Project, Zou's research team successfully developed the first and only Hp vaccine 1. 1 new drug certificate with completely independent intellectual property rights in the world. The research team took the lead in establishing the design principle and key technology of "intramolecular adjuvant subunit mucosal vaccine" in the world, which provided a brand-new idea and reference for the research of new vaccines for mucosal infection pathogens. Established a national biomedical research and development platform such as the National Immune Biological Products Engineering Technology Research Center, which promoted and promoted the technological innovation and development of the industry; The project authorized 4 international PCT patents and 2 national invention patents 12, and successively won the first prize of Chongqing Technological Invention and the second prize of National Technological Invention, and trained 25 postdoctoral, doctoral and master students 125.

The Lancet magazine is one of the most authoritative academic journals in the medical field in the world at present, and it is also one of the SCI journals with the highest impact factor. The impact factor in 20 14 years is 45.5438+07.

Is the postgraduate entrance examination policy unclear? Is Shen Shuo confused with the same academic level? Is it difficult to choose a college major? Click on official website below, and a professional teacher will answer your questions. 2 1 1/985 postgraduate master/doctor open network application name: /yjs2/